Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and thank you for standing by. My name is Lacey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma First Quarter 2025 Financial Results and Business Update Conference Call. All lines have been placed on mute to prevent any background noise. After speaker remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would now like to turn the call over to Henry Wheeler, Vice President of Investor and Relations. You may go ahead. Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release for our Q1 2025 business update and financial results. We look forward to highlighting the progress made during the year to date, as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of our website. On slide two, before we start, I'd like to remind you that we'll be making forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. On slide three, to cover today's agenda, After an introduction from Jonathan, our CEO, Yanis Morel, Chief Operating Officer, will discuss the preclinical ANCET platform and ADC updates. Sonia Quarantino, our Chief Medical Officer, will cover the clinical updates on the Kutumab 6501 and 4502, who will then hand the call to Jonathan to wrap and close. We also have Frederick, our CFO, on the line for Q&A...